Skip to main content
SpringerLink
Log in

Pre-clinical studies using OxyVita hemoglobin, a zero-linked polymeric hemoglobin: a review

  • Review Article
  • Published:
Journal of Artificial Organs Aims and scope Submit manuscript

Abstract

Hemoglobin-based oxygen carriers (HBOC) are being developed to provide the oxygen necessary in clinical situations when whole blood is not available. The safety and effectiveness of each HBOC must be determined before clinical approval. In the past several years animal studies have been conducted with zero-linked polymers to evaluate their effectiveness at delivering oxygen in vivo. Studies have addressed issues associated with interstitial extravasation, cerebral ischemia and blood flow, resuscitation, and coagulation interactions. Several of the investigations reviewed are based on early preparations of zero-linked polymerized bovine hemoglobins (ZL-HbBv), which contained a wide range of high-molecular-weight polymers. Recent studies using the Oxyvita product OxyVita Hb, which contains a more homogenous population (97%) of large-molecular-weight species (~17 MDa), are also included in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Estep T, Bucci E, Farmer M, Greenberg G, Harrington JP, Kim HW, Klein H, Mitchell P, Nemo G, Olsen K, Palmer A, Valeri R, Winslow R. Basic science focus on blood substitutes: a summary of the NHLBI division of blood diseases and resources working group workshop. Transfusion. 2008;48:776–82.

    Article  PubMed  Google Scholar 

  2. Buchler PW, Alayash AI. All hemoglobin-based oxygen carriers are not created equally. Biochim Biophys Acta. 2008;1784:1378–81.

    Google Scholar 

  3. Hirsch RE, Harrington JP. Blood substitutes: an overview and perspective. Einstein Q J Biol Med. 2000;17:113–23.

    CAS  Google Scholar 

  4. Razynska A, Bucci E. Zero-link polymerization: a new class of polymeric hemoglobins. In: Tsuchida E, editor. Blood substitutes-present and future perspectives. Amsterdam: Elsevier; 1998. p. 265–79.

    Chapter  Google Scholar 

  5. Harrington JP, Wollocko J, Kostecki E, Wollocko H. Physicochemical characteristics of OxyVita Hb, a zero-linked polymer: liquid and powder preparations. Artif Cells Blood Substit Biotechnol. 2010;38 (in press).

  6. Urbaitis B, Razynska A, Corteza Q, Fronticelli C, Bucci E. Intravascular retention and renal handling of purified natural and intramolecularly crosslinked hemoglobins. J Lab Clin Med. 1991;117:115–21.

    CAS  PubMed  Google Scholar 

  7. Snyder SR, Welty EV, Walder RY, Williams LA, Walder JA. HbXL99 alpha: a hemoglobin derivative that is cross-linked between the alpha subunits is useful as a blood substitute. Proc Natl Acad Sci USA. 1987;84:7280–4.

    Article  CAS  PubMed  Google Scholar 

  8. D’Agnillo F, Alayash AI. Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin. Adv Drug Deliv Res. 2000;40:199–212.

    Article  Google Scholar 

  9. Olsen JS, Foley EW, Rogge C, Tsai AL, Doyle MP, Lemon DD. NO scavenging and the hypertensive effect of hemoglobin-based oxygen carriers. Free Radic Biol Med. 2004;36:685–97.

    Article  Google Scholar 

  10. Acharya SK, Freidman JM, Manjula BN, Intaglietta M, Tsai G, Winslow RM, Malavalli S, Vandergriff K, Smith PK. Enhanced molecular volume of conservatively pegylated Hb: (SP-PEG5K)6-HbA is non-hypertensive. Artif Cells Blood Substit Immobil Biotechnol. 2005;33:239–55.

    Article  CAS  PubMed  Google Scholar 

  11. Alayash AI, D’Agnillo F, Beuhler PW. First generation blood substitutes: what have we learned? Biochemical and physiological perspectives. Expert Opin Biol Ther. 2007;7:665–75.

    Article  CAS  PubMed  Google Scholar 

  12. Winslow RM. Cell-free oxygen carriers: scientific foundations, clinical development, and new directions. Biochim Biophys Acta. 2008;1784:1382–6.

    CAS  PubMed  Google Scholar 

  13. Matheson B, Kwansa HE, Bucci E, Rebel A, Koehler RC. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol. 2002;93:1479–86.

    CAS  PubMed  Google Scholar 

  14. Rebel A, Ulatowski JA, Kwansa H, Bucci E, Koehler RC. Cerebrovascular response to decreased hematocrit: effect of cell-free hemoglobin, plasma viscosity, and CO2. Am J Physiol Heart Circ Physiol. 2003;285:1600–8.

    Google Scholar 

  15. Mito T, Nemoto M, Kwansa H, Sampei K, Habeeh M, Murphy SJ, Bucci E, Koehler RC. Decreased damage from transient focal cerebral ischemia by transfusion of zero-linked hemoglobin polymers in mouse. Stroke. 2009;40:278–84.

    Article  CAS  PubMed  Google Scholar 

  16. Reynolds PS, Barbee RW, Skaflen MD, Ward KR. Low-volume resuscitation cocktail extends survival after severe hemorrhagic shock. Shock. 2007;28:45–52.

    Article  CAS  PubMed  Google Scholar 

  17. Jahr JS, Weeks DL, Desai P, Lim JC, Butch W, Gunther R, Driessen B. Does OxyVita, a new-generation hemoglobin-based-oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% Hetastarch? A ex vivo thromboelastography study. J Cardiothorac Vasc Anesth. 2008;22:34–9.

    Article  PubMed  Google Scholar 

  18. Moallempour M, Jahr JS, Lim JC, Weeks D, Butch AW, Dreissen B. Methemoglobin effects on coagulation: a dose-response study with HBOC-200 (OxyGlobin) in a thromboelastogram model. J Cardiothorac Vasc Anesth. 2009;23:41–7.

    Article  CAS  PubMed  Google Scholar 

  19. Sampei K, Ulatowski JA, Asano Y, Kwansa H, Bucci E, Koehler RC. Role on nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion. Am J Physiol Heart Circ Physiol. 2005;289:H1191–201.

    Article  CAS  PubMed  Google Scholar 

  20. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls: the two pore theory. Physiol Rev. 1994;74:163–219.

    CAS  PubMed  Google Scholar 

  21. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke. Stroke. 1988;19:464–71.

    Google Scholar 

  22. The Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. Stroke. 1989;20:317–23.

    Google Scholar 

  23. Klaus JA, Kibler KK, Abuchhowski A, Kohler RC. Early treatment of transient focal cerebral ischemia with bovine PEGylated carboxy hemoglobin transfusion. Artif Cells Blood Substit Biotechnol. 2010;38:223–9.

    Article  CAS  Google Scholar 

  24. Strauss RG, Pennell BJ, Stump DC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion. 2002;42:27–36.

    Article  CAS  PubMed  Google Scholar 

  25. Huraux C, Ankri A, Eyraud D. Hemostatic changes in patients receiving hydroxyethyl starch: the influence of ABO blood group. Anesth Analg. 2001;92:1396–401.

    Article  CAS  PubMed  Google Scholar 

  26. Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thromboelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86:575–8.

    Article  CAS  PubMed  Google Scholar 

  27. Essex DW, Li M. Redox modification of platelet glycoproteins. Curr Drug Targets. 2006;7:1233–41.

    Article  CAS  PubMed  Google Scholar 

  28. Harrington JP, Orlig K, Zito SL, Wollocko J, Wollocko H. Structural and redox behavior of OxyVita Hb, a zero-linked polymeric hemoglobin: comparison with natural acellular polymeric hemoglobins. Artif Cells Blood Substit Biotechnol. 2010;38:64–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry, State University of New York, 1 Hawk Drive, New Paltz, NY, 12561, USA

    John P. Harrington

  2. Oxyvita, Inc., 108 World Trade Way, New Windsor, NY, 12553, USA

    John P. Harrington & Hanna Wollocko

Authors
  1. John P. Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hanna Wollocko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John P. Harrington.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harrington, J.P., Wollocko, H. Pre-clinical studies using OxyVita hemoglobin, a zero-linked polymeric hemoglobin: a review. J Artif Organs 13, 183–188 (2010). https://doi.org/10.1007/s10047-010-0528-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10047-010-0528-6

Keywords

Search

Navigation